Fast™
Identification of at-risk NASH patients
The state-of-the-art non-invasive solution for liver disease management, affordable to all.
Powered by LSM by VCTE™ and CAP™ for liver fibrosis and steatosis management.
Supported by 3,500+ peer reviewed publications and 160+ guidelines.
Not suitable for all practice organizations. Please contact Echosens to determine if FibroScan® GO is the best fit for your practice needs.
Comprehensive and flexible pay-per-exam offer.
All services included.
Screening of at-risk patients for early intervention.
Simple, quick, non-invasive and painless examination.
Interpretation tools and calculation of clinical scores
to support in making instant medical decisions for patients.
Assists in monitoring staged progression of liver disease
which may lead to improved patient outcomes.
Perform the examination with FibroScan® and interpretation
to determine the fibrosis stage and the steatosis grade.
Calculate FIB-4 and combined scores.
Generate consolidated and personalized medical reports.
Consult and visualize the history of your patients’ results.
Assists with onsite installation and training.
Includes maintenance, annual calibration of probes and both software upgrades and updates.
Easy access to continuous training and users community with Echosens Academy.
Not suitable for all practice organizations. Please contact Echosens to determine if FibroScan® GO is the best fit for your practice needs.
Equipment compatible with an S+ probe (sold separately).
The FibroScan® 230 is intended to provide shear wave speed measurements and estimates of tissue stiffness as well as ultrasound coefficient of attenuation (CAP: Controlled Attenuation Parameter) in internal structures of the body. The Shear wave speed and stiffness measurements may be used as an aid to clinical management of adult patients with liver disease. FibroScan® 230 is indicated for non-invasive measurement in the liver of 50 Hz shear wave speed and estimates of stiffness as well as determining a 3.5 MHz ultrasound coefficient of attenuation (CAP: Controlled Attenuation Parameter). Shear wave speed, stiffness and CAP may be used as an aid to diagnosis and monitoring of adult patients with liver disease, as part of an overall assessment of the liver. Shear wave speed, stiffness and CAP may be used as an aid in the clinical management of pediatric patients with liver disease.
All personal and health data generated by the FibroScan® GO solution is managed in compliance with HIPAA regulations. Data located on Echosens Cloud is managed by an ISO27001 certified organization.
1. Wong VW, et al. Noninvasive biomarkers in NAFLD and NASH – current progress and future promise. Nat Rev Gastroenterol Hepatol. 2018;15(8):461-478.
2. European Association for Study of Liver; Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol. 2015;63(1):237-264.
3. Steadman R, et al. A health technology assessment of transient elastography in adult liver disease. Can J Gastroenterol. 2013;27(3):149-158.
To access the FibroScan® 230 user guides, connect to the Echosens Cloud
Learning Center > FibroScan® GO
Identification of at-risk NASH patients
Identification of advanced fibrosis in NAFLD patients.
Identification of cirrhosis in NAFLD patients.
Enhance your FibroScan® capabilities for improved management of fatty liver patients